| Gastroenterology Consultants Of Laredo | |
|
6999 Mcpherson Rd Suite 220 Laredo TX 78041-6449 | |
| (956) 795-4776 | |
| (956) 795-0882 |
| Full Name | Gastroenterology Consultants Of Laredo |
|---|---|
| Speciality | Internal Medicine |
| Location | 6999 Mcpherson Rd, Laredo, Texas |
| Authorized Official Name and Position | Elsa S. Canales (PRESIDENT) |
| Authorized Official Contact | 9567954776 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Gastroenterology Consultants Of Laredo 6999 Mcpherson Rd Suite 220 Laredo TX 78041-6449 Ph: (956) 795-4776 | Gastroenterology Consultants Of Laredo 6999 Mcpherson Rd Suite 220 Laredo TX 78041-6449 Ph: (956) 795-4776 |
| NPI Number | 1154486108 |
|---|---|
| Provider Enumeration Date | 12/27/2006 |
| Last Update Date | 08/11/2017 |
| Medicare PECOS PAC ID | 3577538495 |
|---|---|
| Medicare Enrollment ID | O20040901001315 |
News Archive
Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel's Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.
ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.
Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo.
People who are able to comfortably converse during exercise are likely working out at an acceptable intensity. This guideline, known as the "Talk Test," has been shown to correctly gauge intensity and correspond to an effective range for exercise prescription.
The current issue of Psychotherapy and Psychosomatics reports an article that analyzes the data that are available on what may happen when psychotropic drugs are discontinued.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154486108 | NPI | - | NPPES |
| 152440702 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | (* (Not Available)) | Primary |
| Provider Name | Elsa S Canales |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1477618429 PECOS PAC ID: 1557336484 Enrollment ID: I20040901001341 |
News Archive
Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel's Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.
ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.
Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo.
People who are able to comfortably converse during exercise are likely working out at an acceptable intensity. This guideline, known as the "Talk Test," has been shown to correctly gauge intensity and correspond to an effective range for exercise prescription.
The current issue of Psychotherapy and Psychosomatics reports an article that analyzes the data that are available on what may happen when psychotropic drugs are discontinued.
› Verified 1 days ago
| Provider Name | Michael A Tijerina |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881095453 PECOS PAC ID: 8022230259 Enrollment ID: I20141104000088 |
News Archive
Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel's Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.
ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.
Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo.
People who are able to comfortably converse during exercise are likely working out at an acceptable intensity. This guideline, known as the "Talk Test," has been shown to correctly gauge intensity and correspond to an effective range for exercise prescription.
The current issue of Psychotherapy and Psychosomatics reports an article that analyzes the data that are available on what may happen when psychotropic drugs are discontinued.
› Verified 1 days ago
| Provider Name | Alfredo Camero |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1881954030 PECOS PAC ID: 6709197452 Enrollment ID: I20150622001410 |
News Archive
Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel's Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.
ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.
Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo.
People who are able to comfortably converse during exercise are likely working out at an acceptable intensity. This guideline, known as the "Talk Test," has been shown to correctly gauge intensity and correspond to an effective range for exercise prescription.
The current issue of Psychotherapy and Psychosomatics reports an article that analyzes the data that are available on what may happen when psychotropic drugs are discontinued.
› Verified 1 days ago
| Provider Name | Griselda Salas |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1669653028 PECOS PAC ID: 3678863552 Enrollment ID: I20160606001115 |
News Archive
Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel's Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.
ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.
Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo.
People who are able to comfortably converse during exercise are likely working out at an acceptable intensity. This guideline, known as the "Talk Test," has been shown to correctly gauge intensity and correspond to an effective range for exercise prescription.
The current issue of Psychotherapy and Psychosomatics reports an article that analyzes the data that are available on what may happen when psychotropic drugs are discontinued.
› Verified 1 days ago
| Provider Name | Blanca A Castro |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639614662 PECOS PAC ID: 5193080315 Enrollment ID: I20180517001021 |
News Archive
Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel's Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.
ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.
Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo.
People who are able to comfortably converse during exercise are likely working out at an acceptable intensity. This guideline, known as the "Talk Test," has been shown to correctly gauge intensity and correspond to an effective range for exercise prescription.
The current issue of Psychotherapy and Psychosomatics reports an article that analyzes the data that are available on what may happen when psychotropic drugs are discontinued.
› Verified 1 days ago
News Archive
Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel's Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.
ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.
Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo.
People who are able to comfortably converse during exercise are likely working out at an acceptable intensity. This guideline, known as the "Talk Test," has been shown to correctly gauge intensity and correspond to an effective range for exercise prescription.
The current issue of Psychotherapy and Psychosomatics reports an article that analyzes the data that are available on what may happen when psychotropic drugs are discontinued.
› Verified 1 days ago
Jesus S Pineda M.d.p.a. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 201 W Del Mar Blvd, 7a, Laredo, TX 78041 Phone: 956-727-0849 Fax: 956-712-2814 | |
Clear Choice Laredo Hospital Physicians Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 6406 Mcpherson Rd Ste 5, Laredo, TX 78041 Phone: 956-625-2730 | |
Andres Garcia Zuniga Md Pa Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1203 Welby Ct, Laredo, TX 78041 Phone: 956-794-8840 Fax: 956-794-8844 | |
Gomez-vazquez Family Practice, Pa Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7210 Mcpherson Rd, Suite #115, Laredo, TX 78041 Phone: 956-722-8046 Fax: 956-722-8047 | |
Gateway Community Health Center, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1515 Pappas, Laredo, TX 78040 Phone: 956-795-8100 | |
Dr Ramon De La Torre Md Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 220 W Hillside Rd Ste 9, Laredo, TX 78041 Phone: 956-724-5656 Fax: 956-724-1344 | |
Gateway Community Health Center, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1515 Pappas St, Laredo, TX 78041 Phone: 956-795-8100 Fax: 956-795-8135 |